1. Introduction {#sec0005}
===============

Targeted pacing site is fundamental in cardiac resynchronization therapy to achieve reverse left ventricular (LV) remodeling.[@bib0050], [@bib0055] The recently released active fixation LV lead Attain^®^ Stability™ (Model 20066, Medtronic Inc, Maastricht, the Netherlands) enables a targeted pacing site at no compromise with the risk of lead dislodgement[@bib0060], [@bib0065] or phrenic nerve stimulation, and with an acceptable LV pacing threshold[@bib0060] regardless of vein length and size.[@bib0065] The challenge for the active fixation lead is the feasibility of extraction, given the former experience with the deployable-lobes Starfix lead (Medtronic Inc., Minneapolis, MN). The Attain^®^ Stability™ features a side helix as fixation mechanism, which has proven easy to be extracted in the experimental model. We report a case where LV extraction occurred about 7 months after implantation because of pocket infection.

2. Case report {#sec0010}
==============

An 83-year-old woman had recurrent hospital admissions along 3 years with severe congestive heart failure (NYHA III to IV) due to idiopathic dilated cardiomyopathy, permanent atrial fibrillation, wide QRS (160 ms) with complete left bundle branch block morphology, and severe left ventricular dysfunction (LV ejection fraction = 27%). The patient was successfully implanted with CRT-P (Consulta, Medtronic, Minneapolis, MN) with a 5076 CapSureFix Novus Lead in right ventricle and an active fixation left ventricular lead in a mid-part of a postero-lateral vein of the coronary sinus (Attain^®^ Stability™ Model 20066 LV lead; Medtronic, Inc, Tilburg, the Netherlands) that matched with the target pacing site as observed by pre-operative strain analysis at echocardiography. This target pacing site was concordant with the intraoperative Q-LV measurement, LV depolarization occurring after the termination of the QRS complex. Atrio-ventricular node ablation was performed concomitantly during the procedure because of a very difficult rate control with drugs (resting heart rate \> 70 bpm on metoprolol + diltiazem with symptomatic hypotension); only metoprolol 50 mg daily was given at follow-up.

The patient had clinical improvement and diuretics were gradually decreased. Seven months after CRT-P implantation, the patient showed fever (37.8 °C) and an inflammatory skin reaction at the pacemaker pocket. Laboratory: white blood cells 4400/mmc, red blood cells 3,960,000/mmc, platelet 147,000/μL, C-reactive protein mildly increased at 1.45 mg/dl, blood cultures negative. At echocardiography, no vegetations were detected on the leads; the patient was a CRT super-responder based on normalization of left ventricular volume (50% reduction of end systolic volume) and of LV ejection fraction (increased to 60%). Positron emission tomography (PET) scan was highly suggestive of pocket inflammation/infection (SUV max = 8.9), and showed no abnormal findings endovascular and at other sites. Skin thinning and reddening progressed over one week.

Empirical antibiotic therapy against staphylococci was started with i.v. vancomycin and rifampicin and the fever subsided. After 3 days, the CRT-P system was explanted from the left side. The active fixation lead was removed as per the manufacturer\'s recommended technique without any problem: after insertion of a regular stylet, the lead was turned counter-clockwise (around 8--10 turns) and then traction was applied with a mild force (same force needed as with others left ventricular passive leads, close to the 0.5--1 kg as mentioned in the training). On visual examination, the fixation helix appeared elongated ([Fig. 1](#fig0005){ref-type="fig"}). The patient was nearly pacemaker-dependent with an escape rhythm at 30 bpm, so a new CRT-P system was implanted right-sided. Owing to a nearly complete thrombosis of the coronary vein previously hosting the LV lead, venoplasty with repeated inflations of a 4 mm × 8 mm balloon was performed, in order to place again the LV lead at the same target site and maintain the CRT super-response ([Fig. 2](#fig0010){ref-type="fig"}A--D). A new Attain^®^ Stability™ was implanted with good electrical parameters. The culture of the explanted device revealed *Staphylococcus aureus* infection; hence, the patient was treated with i.v. vancomycin and oral rifampicin for 4 weeks. Neither fever nor pocket infection was observed during 6 months follow-up.

All electrical parameters of pacemaker were regular (right ventricular and LV sensing respectively 11.5 mV and 6.8 mV, with capture threshold respectively 0.3 V and 1.5 V and impedance was respectively 471 Ω and 839 Ω).

3. Discussion {#sec0015}
=============

The possibility to target an LV stimulation site regardless of vein length and size is a great opportunity to increase the chances of response to CRT, and to prevent lead dislodgement and phrenic stimulation. The design of the Attain^®^ Stability™ allows an easy disengagement at the "distal" level (the target vein), owing to the different conception compared to the Starfix lead. Stabilization with lead stenting has also proved effective and amenable to uncomplicated lead extraction.[@bib0060], [@bib0070] Though more data on long-implanted leads are awaited, the grade of lead engagement along the thoracic veins course cannot be anticipated as different from any other 4F LV lead. Thus, we believe that this technological improvement should enhance the adoption of active fixation LV leads, the perception of limited extractability being its major opponent in the clinicians' opinion. In this patient, a targeted lead placement was coupled to AV node ablation owing to a difficult rate control during AF, as recommended in literature,[@bib0075], [@bib0080] resulting in a super-responder. The timing of re-implantation after pocket infection was dictated by the risk of complete coronary vein thrombosis at short term, that might have precluded a successful lead re-implantation and CRT delivery, as previously reported by Burke et al.[@bib0085] in patients with indwelling leads for longer than 3 months. Moreover, the absence of endovascular infection (blood culture, PET, echocardiography) supported an early re-implantation strategy.[@bib0090]
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![Re-implantation of a new Attain^®^ Stability™ lead. *Legends*: coronary sinus angiogram after lead extraction (A), venoplasty with multiple balloon inflations starting from the distal portion of the coronary vein up to its take-off from the coronary sinus (B), coronary sinus angiogram after the venoplasty (C), Attain^®^ Stability™ lead final placement (D).](gr2){#fig0010}
